Seelos Therapeutics Inc. (SEEL)

$0.25

up-down-arrow $-0.92 (-78.63%)

As on 17-Dec-2024 09:30EDT

Market cap

info icon

$0 Mln

Revenue (TTM)

info icon

$2 Mln

P/E Ratio

info icon

0

P/B Ratio

info icon

15.1

Div. Yield

info icon

0 %

Seelos Therapeutics (SEEL) Share Price

Compare

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 0.25 High: 0.35

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -5.8 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    37.91

  • EV/EBITDAEV/EBITDA information

    2.4

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $2

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    581,000

10 Years Aggregate

CFO

$-247.05 Mln

EBITDA

$-300.14 Mln

Net Profit

$-308.32 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Seelos Therapeutics (SEEL)
-98.9 -- -91.6 -99.0 -93.2 -78.7 -73.7
BSE Sensex*
-9.6 -2.7 2.9 -5.0 5.4 5.7 10.4
As on 17-Dec-2024  |  *As on 04-Sep-2026
Company
2023
2022
2021
2020
2019
2018
2017
Seelos Therapeutics (SEEL)
-93.2 -58.3 3.2 17.9 -76.7 -89.4 41.5
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9
BSE Sensex
18.7 4.4 22.0 15.8 14.4 5.9 27.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Seelos Therapeutics (SEEL)
0.3 0.2 2.0 4.1 -1,480.7 -- 0 15.1
17.4 6,074.3 3,117.6 157.4 14.7 -- 36.3 186.5
206.5 10,424.8 776.6 -191.6 -17.6 -223.4 -- 129.6
74.2 14,974.8 691.8 -696.2 -89.1 -- -- 123.7
111.2 12,310.3 830.8 54.9 3.2 8.1 264.8 17.9
12.0 10,020.9 332,834.2 33,166.6 11.1 8.9 29.3 2.5
24.4 12,236.5 5,020.0 -199.0 1.6 -3 -- 1.9
287.5 5,591.7 290.5 197.2 82.5 19.9 28.9 5.9
68.4 6,058.9 450.9 138.6 39.1 115.6 50.1 32.1
124.7 8,865.6 431.8 -136.7 -30.8 -30.3 -- 21.5

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Seelos Therapeutics (SEEL)

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an...  intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. 

  • Founder, Chairman, CEO & President

    Dr. Raj Mehra J.D., Ph.D.

  • Founder, Chairman, CEO & President

    Dr. Raj Mehra J.D., Ph.D.

  • Headquarters

    New York, NY

  • Website

    https://seelostherapeutics.com

FAQs for Seelos Therapeutics (SEEL)

The share price of Seelos Therapeutics Inc (SEEL) is $0.25 (NASDAQ) as of 17-Dec-2024 09:30 EDT. Seelos Therapeutics Inc (SEEL) has given a return of -93.16% in the last 3 years.

Since, TTM earnings of Seelos Therapeutics Inc (SEEL) is negative, P/E ratio is not available.
The P/B ratio of Seelos Therapeutics Inc (SEEL) is 15.10 times as on 17-Dec-2024, a 96 premium to its peers’ median range of 7.69 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
-0.36
-0.41
2022
-0.03
-0.23
2021
-0.08
0.10
2020
-0.15
1.10
2019
-0.02
-172.52

The 52-week high and low of Seelos Therapeutics Inc (SEEL) are Rs -- and Rs -- as of 06-Sep-2026.

Seelos Therapeutics Inc (SEEL) has a market capitalisation of $ 0 Mln as on 17-Dec-2024. As per SEBI classification, it is a company.

Before investing in Seelos Therapeutics Inc (SEEL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.

loading...
loading...